IPI-145

CHF 126.00
In stock
SYN-1175-M0011 mgCHF 126.00
SYN-1175-M0055 mgCHF 198.00
SYN-1175-M01010 mgCHF 329.00
SYN-1175-M05050 mgCHF 1'113.00
SYN-1175-M100100 mgCHF 1'963.00
 
More Information
Product Details
Synonyms IPI 145
Product Type Chemical
Properties
Formula C22H17ClN6O
MW 416.9
CAS 1201438-56-3
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: mTOR - PI3K | Kinase Group: Atypical (PIKK) | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key SJVQHLPISAIATJ-ZDUSSCGKSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
IPI-145 is a potent, oral inhibitor of Class I phosphoinositide-3-kinase (PI3K)-δ and PI3K-γ (IC(50) of 243 pM and 50nM), and is clinically active in patients with advanced hematological malignancies.
Product References
  1. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models: D.G. Winkler, et al.; Chem. Biol. 20, 1364 (2013)
  2. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis: D.L. Boyle, et al.; J. Pharmacol. Exp. Ther. 348, 271 (2014)
  3. IPI-145 shows promise in CLL patients: Cancer Discov. 4, 136 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.